4
Changes in Ownership
Bicara Therapeutics Inc. Filed Acc 0001628280-26-020236
Chief Executive Officer sold 15,000 shares at an average $18.82 ($282,366)
- Chief Executive Officer acquired 15,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Mazumdar Claire Chief Executive Officer | 2026-03-18 | Option exercise 10b5-1 | +6,499 | $3.79 | $24,630 | 345,891 | D |
| Mazumdar Claire Chief Executive Officer | 2026-03-18 | Sale 10b5-1 | −6,499 | $18.84 | $122,415 | 339,392 | D |
| Mazumdar Claire Chief Executive Officer | 2026-03-19 | Option exercise 10b5-1 | +6,905 | $3.79 | $26,169 | 346,297 | D |
| Mazumdar Claire Chief Executive Officer | 2026-03-19 | Sale 10b5-1 | −6,905 | $18.78 | $129,705 | 339,392 | D |
| Mazumdar Claire Chief Executive Officer | 2026-03-20 | Option exercise 10b5-1 | +1,596 | $3.79 | $6,049 | 340,988 | D |
| Mazumdar Claire Chief Executive Officer | 2026-03-20 | Sale 10b5-1 | −1,596 | $18.95 | $30,246 | 339,392 | D |
| Derivatives | |||||||
| Mazumdar Claire Chief Executive Officer | 2026-03-18 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,499 | 184,608 | D | ||
| Mazumdar Claire Chief Executive Officer | 2026-03-19 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,905 | 177,703 | D | ||
| Mazumdar Claire Chief Executive Officer | 2026-03-20 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,596 | 176,107 | D | ||
| Open-market sales · 15,000 sh · avg $18.82 · $282,366 | |||||||
Loading xslF345X06/wk-form4_1774040575.xml…